Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 5:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Anthrax Infection Clear all
Suspended Phase 1 Interventional Accepts healthy volunteers

Ph1 Study of Valortim and Ciprofloxacin in Humans

NCT00964561
View directory record Official record
Conditions
Anthrax
Interventions
Ciprofloxacin and Valortim, Placebo Antibiotic and Valortim, Placebo Antibiotic and Placebo Valortim
Drug · Other
Lead sponsor
PharmAthene, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2010 · Synced Sep 26, 2026, 5:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy Participants

NCT05320094
View directory record Official record
Conditions
Healthy Participants
Interventions
Mavacamten, Activated Charcoal with Sorbitol
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 26, 2026, 5:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study

NCT04067011
View directory record Official record
Conditions
Anthrax
Interventions
Ciprofloxacin 500Mg Tablet, Doxycycline 100Mg Tablet, AV7909
Drug · Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 45 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
4
States / cities
DeLand, Florida • Kansas City, Missouri • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Sep 26, 2026, 5:53 PM EDT
Recruiting Not applicable Interventional

Cigarette Filter Study

NCT07348679
View directory record Official record
Conditions
Smoking ( Cigarette)
Interventions
Charcoal filtered cigarettes with marketing, Charcoal filtered cigarette without marketing, Non-charcoal filtered cigarettes
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
21 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 26, 2026, 5:53 PM EDT
Completed No phase listed Observational

Evaluation of the Clinical Specificity of the Active Anthrax Detect™ Plus (AAD Plus) Lateral Flow Immunoassay (LFI)

NCT04320485
View directory record Official record
Conditions
Anthrax
Interventions
Active Anthrax Detect™ Plus (AAD Plus)
Diagnostic Test
Lead sponsor
InBios International, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Tempe, Arizona • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Sep 26, 2026, 5:53 PM EDT
Completed No phase listed Observational

Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients

NCT00050310
View directory record Official record
Conditions
Anthrax, Bacillus Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 26, 2026, 5:53 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed

NCT02339155
View directory record Official record
Conditions
Infections, Bacterial
Interventions
AVA, Raxibacumab, Diphenhydramine
Biological · Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 65 Years
Enrollment
573 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
Edgewater, Florida • Overland Park, Kansas • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 26, 2026, 5:53 PM EDT
Completed No phase listed Observational

Febrile Whole Blood Specimen Collection and Testing

NCT03498027
View directory record Official record
Conditions
Febrile Infection, Anthrax
Interventions
TaqMan Bacillus anthracis Detection Kit
Device
Lead sponsor
MRI Global
Industry
Eligibility
2 Years to 89 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Tarpon Springs, Florida • Fall River, Massachusetts • Franklin, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 26, 2026, 5:53 PM EDT
Completed Phase 1 Interventional

Anthrax Vaccine Clinical Trials

NCT00114621
View directory record Official record
Conditions
Anthrax
Interventions
Anthrax Vaccine, Blood Chemistry, Hematology, Urinalysis
Drug · Procedure
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 45 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 26, 2026, 5:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

BioThrax® (Anthrax) Vaccine in Pregnancy Registry

NCT01653392
View directory record Official record
Conditions
Pregnancy Complications, Pregnancy Outcome, Congenital Abnormalities
Interventions
Observational Intervention
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 26, 2026, 5:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults

NCT01491607
View directory record Official record
Conditions
Anthrax
Interventions
BioThrax
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
4
States / cities
Miami, Florida • Rochester, New York • Mt. Pleasant, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Sep 26, 2026, 5:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

NasoShield in Healthy Adults to Study Safety and Immunogenicity

NCT04415749
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NasoShield, Placebo
Biological · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Sep 26, 2026, 5:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers

NCT01929226
View directory record Official record
Conditions
Inhalational Anthrax
Interventions
ETI-204, Placebo
Biological · Other
Lead sponsor
Elusys Therapeutics
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced Sep 26, 2026, 5:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults

NCT04148118
View directory record Official record
Conditions
Anthrax
Interventions
BW-1010: 50 µg - sprayer - IN, BW-1010: 50 µg - pipette - IN, BW-1010: 100 µg - sprayer - IN, BW-1010: 100 µg - pipette - IN, Saline (Placebo) - sprayer - IN, Saline (Placebo) - pipette - IN, BioThrax (positive control) - SC
Biological
Lead sponsor
BlueWillow Biologics
Industry
Eligibility
18 Years to 49 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Sep 26, 2026, 5:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum

NCT00448253
View directory record Official record
Conditions
Symptoms of Inhalational Anthrax
Interventions
NP-015
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 55 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 26, 2026, 5:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

VHA Clinicians and Bioterror Events: Interactive Web-based Learning

NCT00123396
View directory record Official record
Conditions
Smallpox, Anthrax
Interventions
BioCASES and BioTESTS
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
9
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 26, 2026, 5:53 PM EDT
Completed No phase listed Observational

Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune Globulin

NCT00031291
View directory record Official record
Conditions
Anthrax
Interventions
Anthrax Immune Globulin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 26, 2026, 5:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed

NCT00170469
View directory record Official record
Conditions
Bacillus Anthracis (Anthrax)
Interventions
AVA, rPA vaccine containing alhydrogel
Biological
Lead sponsor
PharmAthene UK Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
16
States / cities
Huntsville, Alabama • Mobile, Alabama • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2008 · Synced Sep 26, 2026, 5:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

BARDA Securing Anthrax Immunity For the Elderly

NCT03518125
View directory record Official record
Conditions
Anthrax
Interventions
BioThrax, AV7909, Sodium chloride injection USP, 0.9% (placebo)
Biological · Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Lenexa, Kansas • Mt. Pleasant, South Carolina • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Sep 26, 2026, 5:53 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Effect of Activated Charcoal on Serum Osmolality, Osmolal Gap, and Enzymatic Ethylene Glycol Assay

NCT07220031
View directory record Official record
Conditions
Osmolality Disturbance, Lab Interference
Interventions
Activated Charcoal
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 26, 2026, 5:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Monoclonal Antibody for Treatment of Inhalation Anthrax

NCT00138411
View directory record Official record
Conditions
Bacillus Anthracis (Anthrax)
Interventions
Ciprofloxacin 500 mg, ETI-204 (Anthim)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Sep 26, 2026, 5:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults

NCT01263691
View directory record Official record
Conditions
Bacillus Anthracis (Anthrax) Infection
Interventions
BioThrax, AV7909 Formulation 1, AV7909 Formulation 2, AV7909 Formulation 3, AV7909 Formulation 4, Control
Biological · Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 50 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
3
States / cities
Miami, Florida • Raleigh, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 26, 2026, 5:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Anthrax AV7909 Boost Evaluation Study

NCT05997264
View directory record Official record
Conditions
Anthrax
Interventions
AV7909 Full Dose (0.5 mL), AV7909 Half Dose (0.25 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL)
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 65 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
7
States / cities
Hickory, North Carolina • Salisbury, North Carolina • Statesville, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 26, 2026, 5:53 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

NCT00845650
View directory record Official record
Conditions
Anthrax
Interventions
AIGIV 3.5 mg/kg, Gamunex 90 mg/kg, AIGIV 7.0 mg/kg, Gamunex 180 mg/kg, AIGIV 14.0 mg/kg, Gamunex 360 mg/kg
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 65 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 26, 2026, 5:53 PM EDT